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Background: Tryptophan hydroxylase-2 (TPH2) is a potential candidate gene for screening tic disorder (TD).
Methods: A case–control study was performed to examine the association between the TPH2 gene and TD. The
SequenomW Mass ARRAY iPLEX GOLD System was used to genotype two single nucleotide polymorphisms (SNPs) of
the TPH2 gene in 149 TD children and in 125 normal controls.
Results: For rs4565946, individuals with the TT genotype showed a significantly higher risk of TD than those with TC plus
CC genotypes [odds ratio (OR) =3.077, 95% confidence interval (CI): 1.273–7.437; P = 0.009], as did male TD children with
the TT genotype (OR = 3.228, 95% CI: 1.153–9.040; P = 0.020). The G allele of rs4570625 was significantly more frequent in
TD children with higher levels of tic symptoms (Yale Global Tic Severity Scale, YGTSS) than those in controls among the
male children (OR = 1.684, 95%: 1.097–2.583; P = 0.017]. TD children with severe tic symptoms had significantly higher
frequencies of rs4546946 TT genotype than did normal controls in boys (OR = 3.292, 95% CI: 1.139–9.513; P = 0.022). We
also found that genotype distributions of both SNPs were different between the Asian and European populations.
Conclusions: Our results indicated that the TT genotype of rs4565946 is a potential genetic risk factor for TD, and the
allele G of rs4570625 might be associated with the severity of tic symptoms in boys. These polymorphisms might be
susceptibility loci for TD in the Chinese Han population. Because of the confounding of co-existing attention deficit
hyperactivity disorder (ADHD),these findings need to be confirmed by studies in much larger samples.
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Tic disorder (TD) is a neuropsychiatric disorder charac-
terized by involuntary tics (multiple motor and/or vocal
tics). Tics wax and wane over time and are more intense
in prepubertal boys. A large proportion of affected chil-
dren reach a quiescent stage around early adolescence
[1-3]. Recent epidemiological studies have changed the
traditional perception that TD is rare, and demonstrate
a prevalence rates >1000 per 100000 children [4-7]. Co
morbidity of TD with attention deficit hyperactivity dis-
order (ADHD) and obsessive-compulsive disorder
(OCD) is common [8].* Correspondence: erzhli@yahoo.com; fywjh@163.com
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reproduction in any medium, provided the orThe exact cause of TD is unknown. A heritable compo-
nent is proposed to play a major role in the pathophysi-
ology of TD, as shown by family studies, evaluations of
monozygotic and dizygotic twins, and by follow-up inves-
tigations of at-risk children [9-12]. However, the suscep-
tible genes or relevant DNA sequence variations that
might be involved in the pathogenesis of TD have not
been identified [13,14]. Abnormalities of neurotransmitter
systems such as dopamine and serotonin (5-hydroxytryp-
tamine, 5-HT) are also proposed to contribute to the
symptoms of the disorder. Serotonergic projections from
the dorsal raphe area have been shown to inhibit dopa-
mine function in the striatum and cortex, where they in-
hibit the synaptic release of dopamine, and probably the
synthesis of dopamine. Data from neurochemical studies
have shown that generally decreased concentrations of
5-hydroxyindolacetic acid (5-HIAA) in cerebrospinal fluidLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of study participants
Characteristic TD children Controls P
(n = 149) (n = 125)
Sex (n,%)
Male 112(75.17) 84(67.20)
Female 37(24.83) 41(32.80) 0.470a
Age (Mean ± SD) 8.90 ± 2.78 8.62 ± 2.61 0.220b
Male 8.92 ± 2.76 8.92 ± 2.94 1.000b
Female 8.84 ± 2.92 7.98 ± 1.99 0.129b
Age of onset (year) 6.67 ± 2.80
ADHD comorbidity (n,%)
TD only 114(76.51)
TD + ADHD 35(23.49)
YGTSS (n,%)
low score subgroup 36(23.68)
high score subgroup 116(76.32)
Abbreviations:
TD only, children with only tics.
TD + ADHD, children with tics and ADHD.
a Chi-square test was used to calculate the p- values.
b t test was used to calculate the p- values.
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tion of dopaminergic activity by serotonergic neurons
[15]. Data from pharmacological studies also indicate the
use of serotonin reuptake inhibitors (SRIs) is effective in
tic reduction in some TD children [16,17]. Tryptophan
hydroxylase (TPH) is a rate-limiting enzyme that catalyses
the synthesis of 5-HT from tryptophan [18]. Until re-
cently, it was thought that there was only one gene encod-
ing TPH, referred to as tryptophan hydroxylase isoform
(TPH1). However, TPH knockout studies in mice (mice
TPH−/−) showed normal amounts of 5-HT in certain
brain regions compared to their wild-type siblings (mice
TPH+/+) [19]. Furthermore, TPH knockout mice exhib-
ited no significant differences in 5-HT-related behaviors.
This observation confirmed the hypothesis of the exist-
ence of a second TPH isoform (TPH2) [19]. The expres-
sion of both isoforms of TPH is partially exclusive. Several
studies demonstrate that in humans TPH2 is exclusively
expressed in serotonergic neurons of the brain, with the
predominant expression in the Raphe nuclei of the mid-
brain, whereas TPH1 is mostly expressed in peripheral tis-
sues [20]. TPH2 is located on chromosome 12q21.1; it
spans a region of 93.5 kb and harbors 11 exons [20].
TPH2 is strategically placed to control 5-HT synthesis in
the brain. For this reason, there has been great interest in
identifying genetic variants that affect TPH2 enzymatic ac-
tivity or the expression levels of the TPH2 gene. However,
extensive DNA sequencing of the TPH2 gene has shown
that the polymorphisms change the amino-acid sequence
of the TPH2 protein were rare [21,22]. The research has,
therefore, focused on identifying genetic variants that influ-
ence the TPH2 gene expression [23]. Some studies suggest
that the human TPH2 gene includes several single nucleo-
tide polymorphisms (SNPs) which include G to T base sub-
stitution in the transcriptional control region at position
−703 (rs4570625). Recently, the functional relevance of
rs4570625 in the transcriptional control region of the
TPH2 gene was investigated by many groups [23-26]. In
addition, the haplotype analysis of rs4570625 and
rs4565946 by Mossner et al. found an association between
TD and the G-C haplotype (and to a lesser extent, the T-C
haplotype). This came from the association of the CC geno-
type and the C allele of the intronic SNP rs4565946 [27].
The current study was undertaken to investigate
whether the TPH2 polymorphisms (SNP rs4570625 and
rs4565945) act as susceptibility loci for TD in the Chinese
Han population. We also investigated the possible associ-
ation between these polymorphisms and severity scored
with the Yale Global Tic Severity Scale (YGTSS) [28].
Materials and methods
Study subjects
The characteristics of the study participants are show in
Table 1. A total of 149 children with TD, diagnosedaccording to the DSM-IV-TR criteria [29], were included
in this study. These subjects were recruited from patients
who were admitted to the Department of Neurological
Medicine of Capital Institute of Pediatrics. Individuals
with TD who also had coexisting diagnosis of OCD and
anxiety disorder were excluded. All participants were from
the Chinese Han population with a mean age of 8.90 years
(range: 3 to 17 years). Thirty five children in this TD group
had coexisting ADHD based on DSM-IV-TR criteria.
An additional 125 ethnically matched subjects with a
mean age of 8.62 years (range: 6 to 15 years) were
selected from the general population in Beijing to serve
as a control group. None of the control subjects or their
family had a history of tics, ADHD, OCD, autism, anx-
iety disorder, or other psychiatric diagnoses.
The clinical assessment was made by neurologists in
the Capital Institute of Pediatrics. The protocols for the
study and the written consent were approved by the eth-
ics committee of the Capital Institute of Pediatrics at
Beijing, China (Approval ID: ey2010003).
Assessment of symptom severity
The severity of tic symptoms was scored according to
YGTSS [28], which included a clinician-completed rating
scale and assessment of the overall degree of impair-
ment. Symptom severity was assessed for five separate
domains (number, frequency, intensity, complexity, and
interference), with the defined maximum score of 50.
The mean severity of tic symptoms was 29.61 (range:
10 to 48). Based on the YGTSS, male TD children were
further divided into two groups: a low score subgroup
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than 25) and a high score subgroup with higher levels of
tic symptoms (YGTSS score: 25 or more).DNA extraction and nucleotide sequences
Genomic DNA was extracted from frozen blood samples
for genotyping using a blood and tissue DNA kit (Qiagen,
Germany) according to manufacturer’s instructions. The
concentration (A260 nm) and purity (A260/A280 ratio) of
the DNA were determined with spectrophotometer.
Two single nucleotide polymorphisms (SNPs) found to
represent common allelic variants of TPH2 in the gen-
eral population were chosen for association analyses.
Both SNPs were named in the present study according
to ID numbers from the SNP database (http://www.ncbi.
nlm.nih.gov/SNP/). The positions of the SNPs were
taken from the Hapmap database (http://www.hapmap.
org/). SNP rs4570625 was located in the putative tran-
scriptional control region of TPH2, according to previ-
ously published data [23,30] and in accordance with our
own assessments using an internet-based computational
method (URL:http://thr.cit.nih.gov/molbio/proscan). The
position of the SNP rs4570625 was -703bp upstream of
the transcription start site. The SNP rs4565946 was
located in intron 2 of TPH2.Genotyping
All samples were diluted to a DNA concentration of
20ng/μL. Two tagging SNPs (rs4565946 and rs4570625)
across the TPH2 gene were selected for genotyping
using data from the International Hapmap Project
(2003). SNPs were genotyped using MassARRAY tech-
nology (Sequenom Inc., San Diego, CA, USA). The
iPLEX™ assay was based on post-PCR single-base primer
extension. The assay was performed according to manu-
facturer’s instructions. Forward, reverse and extension
primers were designed using the Assay Design 3.0 soft-
ware of SequenomW (see Additional file 1: Table S1).
The iPLEX ™ reaction products were dispensed onto a
384-well SpectroChip (Sequenom Inc.), and they were
processed and analyzed in a Compact Mass Spectrometer
by Mass ARRAY Workstation 4.0 software (Sequenom
Inc., San Diego, CA, USA).
To ensure consistency, 10% of samples were subjected to
repeat genotyping assay. The accuracy of genotyping was
validated by directly sequencing 10% of the samples. Re-
producibility of the genotyping was high, with 100% con-
cordance between the PCR and SequnomW MassARRAY
and direct sequencing methods.
Sequencing results were analyzed using Mutation Sur-
veyor version 4.0.5 (Softgenetics, State College, Pennsyl-
vania; http://www.softgenetics.com) for alignment and
multiple comparisons.Statistical analysis
Statistical analyses were performed using SSPS version 16.0
for Windows (SPSS, Inc., Chicago, IL, USA). HAPLO-
VIEW 4.1 software was used to evaluate pair wise linkage
disequilibrium (LD) and haplotype frequency between each
tag SNP. Hardy-Weinberg equilibrium, genotype and allele
frequencies of individual SNPs, and YGTSS and genotype
groups at tic severity sections were analyzed using ANOVA
or t tests for continuous variables or by Chi-square (χ2) or
Fisher exact tests for categorical variables. Odds ratios
(OR) with 95% confidence intervals (CI) were calculated to
estimate the risks related to polymorphisms and TD. As
the morbidity associated with TD is higher in males than
in females [4], data from male subjects with TD were ana-
lyzed separately. Genotype and allele distributions of TPH2
SNPs in different ethnic populations were obtained
from the Hapmap database (http://www.hapmap.org/). All
p-values were 2-sided, and p-values <0.05 were considered
statistically significant. For multiple comparisons of
the genotype frequencies using the Bonferroni corrections,
p-values <0.025 were considered significant.
Results
There were no significant differences in age and gender
distributions between the two groups (P > 0.05).
Genotype and allele frequencies of TPH2 polymorphisms
Genotype information was successfully obtained from 274
participants (149 cases and 125 controls). Both SNPs were
found to be in Hardy-Weinberg equilibrium (HWE) in con-
trols (rs4565946: P = 0.49; rs4570625: P = 0.47). There was
a significant deviation from the equilibrium at rs4565946 in
TD children (rs4565946: P = 0.002; rs4570625: P = 1.00).
The distribution of allele and genotypes of the TPH2
polymorphisms in TD children and controls are shown in
Table 2. There was a statistically significant difference in
the genotype distributions of TPH2 rs4565946 between
the TD children and normal controls. Homozygous TT
was significantly higher in TD children than in normal
controls (OR = 3.077, 95%CI, 1.273–7.437; P = 0.018 after
Bonferroni correction). A significantly increased frequency
of the TT genotype was also noticed in male TD children
(OR = 3.228, 95%CI, 1.153–9.040; P = 0.040 after Bonferroni
correction). There was no significant difference in allele
frequency between male TD children and male controls
after Bonferroni correction (P > 0.025) (Table 3).
There were no differences in allele and genotype fre-
quencies of SNP rs4570625, between TD children and
normal controls after Bonferroni correction (P > 0.025).
TD children had nominally higher frequencies of G al-
lele than the normal controls in males (OR = 1.504, 95%
CI, 1.005–2.251; P = 0.047) (Table 3), but the difference
was not statistically significant after Bonferroni correc-
tion (P = 0.047 and P = 0.094).
Table 2 Genotype and Allele frequencies of TPH2 gene polymorphisms between children with TD and normal controls




TPH2 rs4565946 125 149
CC 65 (52.00) 78 (52.35) 1.00
CT 53 (42.40) 48 (32.21)` 1.168 0.28 0.755 [0.453–1.258]
TT 7 (5.60) 23 (15.44) 4.994 0.025 2.738 [1.105–6.788]
CC + CT 118 (94.40) 126 (84.56) 1.00
TT 7 (5.60) 23 (15.44) 6.745 0.009 3.077 [1.273–7.437]
C 183 (73.20) 204 (68.46) 1.00
T 67 (26.80) 94 (31.54) 1.474 0.225 1.259 [0.868–1.825]
TPH2 rs4570625 125 149
TT 44 (35.20) 37 (24.83) 1.00
GT 57 (45.60) 75 (50.34) 2.498 0.114 1.565 [0.897–2.730]
GG 24 (19.20) 37 (24.83) 3.127 0.077 1.833 [0.934–3.599]
TT + GT 101 (80.80) 112 (75.17) 1.00
GG 24 (19.20) 37 (24.83) 1.246 0.264 1.390 [0.779–2.483]
T 145 (58.00) 149 (50.00) 1.00
G 105 (42.00) 149 (50.00) 3.499 0.061 1.381 [0.984–1.937]
Abbreviations: TPH2 = tryptophan hydroxylase2.
a Chi-square test was used to calculate the p-values.
Table 3 Genotype and allele frequencies of TPH2 gene polymorphisms between children with TD and normal controls
in the male subgroup





TPH2 rs4565946 84 112
CC 46 (54.76) 58 (51.79)
CT 33 (39.29) 35 (31.25) 0.306 0.580 0.841 [0.456–1.553]
TT 5 (5.95) 19 (16.96) 4.454 0.035 3.014 [1.046–8.685]
CC + CT 79 (94.05) 93 (83.04)
TT 5 (5.95) 19 (16.96) 5.417 0.020 3.228 [1.153–9.040]
C 125 (74.40) 151 (67.41)
T 43 (25.60) 73 (32.59) 2.254 0.133 1.405 [0.900–2.193]
TPH2 rs4570625 84 112
TT 29 (34.52) 29 (25.89)
GT 40 (47.62) 50 (44.64) 0.437 0.508 1.250 [0.645–2.423]
GG 15 (17.86) 33 (29.46) 3.803 0.051 2.200 [0.990–4.888]
TT + GT 69 (82.14) 79 (70.54)
GG 15 (17.86) 33 (29.46) 3.497 0.061 1.922 [0.963–3.833]
T 98 (58.33) 108 (48.21)
G 70 (41.67) 116 (51.79) 3.942 0.047 1.504 [1.005- 2.251]
Abbreviations: TPH2, tryptophan hydroxylase2.
aChi-square test was used to calculate the p- values.
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in the female subgroups were identified for the two poly-
morphisms (shown in Additional file 1: Table S2).
Allelic and genotypic association analyses of TPH2
polymorphisms and severity of TD in male children
ANOVA analyses did not show any genetic effect at ei-
ther SNP in the patient group (shown in Additional file
1: Table S3).Table 4 Allelic and genotypic association analyses of TPH2 po




































a Pearson chi square test was used to calculate the p-values.
bChi-square test was used to calculate the p-values. Fisher exact test was used wheDifferences in symptom severity among genotypes
were found between the high score subgroup of TD chil-
dren, and normal controls in males (Table 4). SNP
rs4570625 showed a significant increase of G-allele in the
high score subgroup (OR = 1.684, 95%CI, 1.097–2.583;
P = 0.034 after Bonferroni correction). A marginal signifi-
cant p-values (P = 0.045) was observed for GG versus GT
plus TT genotypes in the high score subgroup versus
male controls, but this was not significant afterlymorphisms in low score subgroup and high score
Number and frequency (%)
Low score subgroup High score subgroup
25 87
15 (60.00) 43 (49.43)
6 (24.00) 29 (33.33)
4 (16.00) 15 (17.24)
3.708 5.308
0.157 0.070
21 (84.00) 72 (82.76)
4 (16.00) 15 (17.24
2.568 5.273
0.206 0.022
3.010 [0.742–12.205] 3.292 [1.139–9.513]
36 (72.00) 115 (66.09)
14 (28.00) 59 (33.91)
0.115 2.822
0.734 0.093
1.130 [0.557–2.295] 1.491 [0.934–2.380]
25 87
10 (40.00) 19 (21.84)
9 (36.00) 41 (47.13)
6 (24.00) 27 (31.03)
1.117 5.473
0.572 0.065
19 (76.00) 60 (68.97)
6 (24.00) 27 (31.03)
0.467 4.005
0.494 0.045
1.453 [0.496–4.253] 2.070 [1.008–4.252]
29 (58.00) 79 (45.40)
21 (42.00) 95 (54.60)
0.002 5.724
0.967 0.017
1.014 [0.535–1.922] 1.684 [1.097–2.583]
n the sample size was <5.
Table 5 Haplotype frequency between children with TD and normal controls
Haplotypesa Number and frequency (%) χ2 P OR [95% CI]
TD childrenb Normal controlsb
C-T 74(49.60) 72(57.53)
T-G 47(31.15) 33(26.33) 1.172 0.279 1.356 [0.781–2.356]
C-G 28(18.85) 20(15.67) 1.063 0.302 1.411 [0.732–2.718]
aHaplotypes were constructed using rs4565946 and rs4570625 single-nucleotide polymorphisms, from left to right. No T-T haplotype was observed.
b Percentages may not equal 100 because of rounding.
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ever, the high score subgroup had significantly higher fre-
quencies of the SNP rs4546946 TT genotype than did
normal controls in male children (P = 0.044 after Bonfer-
roni correction).
Haplotype analyses and linkage disequilibrium with TPH2
rs4570625 and rs4565946
The two tag SNPs showed a D’ value of 0.933 (r2 =
0.429) suggesting strong linkage disequilibrium (LD). A
two-marker haplotype analysis was performed across the
TPH2 gene with both SNPs. As shown in Table 5, there
was a trend with C-G and T-G haplotypes increase risk
to TD (OR = 1.411, 95%CI, 0.732–2.718; OR = 1.356,
95%CI, 0.781–2.356; respectively), but the differences
were not significant (P > 0.05).
Table 6 shows the frequencies of the estimated 2-
marker haplotypes among TD children and normal con-
trols in males. There was also a trend that C-G and T-G
haplotypes increase risk to TD in males (OR = 1.426, 95%
CI, 0.658–3.091; OR = 1.556, 95%CI, 0.802–3.018; respect-
ively), but the differences were not significant (P > 0.05).
We also compared our results of the two sites with
Hapmap database (http://hapmap.ncbi.nlm.nih.gov/), and
found that genotype and allele distributions were signifi-
cantly different in different ethnic populations, especially
in European populations (P < 0.05) (Table 7).
Transcription factor binding sites
Based on transcription factor binding sites predic-
tion (http://www.cbrc.jp/research/db/ TFSEARCH.
html; Figure 1), promoter rs4570625 (G > T) affects
the binding ability to the CdxA transcription factor.
Intron 2 rs4565946 (C > T) demonstrated no change
in ability to combine with the transcription factor
(Figure 1).Table 6 Haplotype Frequency between children with TD and
Haplotypesa Number and frequency (%)




aHaplotypes were constructed using rs4565946 and rs4570625 single-nucleotide po
b Percentages may not equal 100 because of rounding.Discussion
TD is thought to be caused by a complex interaction of
environmental and biological factors, with multiple
genes acting at distinct neural circuits, such as the brain
serotonin system. Several studies have investigated an
association between the TPH2 gene and other psychi-
atric disorders, but only one study to date has demon-
strated an association between TPH2 and Tourette’s
syndrome (TS) [27]. Mossner et al. investigated an asso-
ciation between two SNPs (rs4570625 and rs4565946) of
the TPH2 gene and TS in German samples and showed
that the C allele and CC genotype of rs4565946 was
associated with TS [27]. This finding is not in line with
our results, which suggest that the C allele is the major
allele for TPH2 rs4565946 in Chinese subjects, indicat-
ing that there are ethnic differences in comparison with
European, Indian, and other populations (Table 7). Our
results do, however, suggest that the T allele of
rs4565946 may be the risk allele in the Chinese Han
population, and that individuals with T allele may be
more susceptible to TD than those with C allele. We,
therefore, propose that the TT genotype might produce
different effects on TD in subjects in different ethnic
groups.
It has been suggested that alteration in TPH2 gene ex-
pression might result in central serotonergic system dys-
function, which may in turn lead to abnormality of
behavior and increased susceptibility to psychiatric dis-
orders such as TS [27]. Chen et al. demonstrated that
the expression of human TPH2 is regulated by both the
5’-UTR and common polymorphisms in the 5’ regula-
tory region of TPH2 [26]. These researchers also suggest
that promoter rs4570625 (−703 G/T) is likely to influ-
ence the transcription rate of TPH2, a proposal supported
by transcription factor binding sites for function pre-
diction (http://www.cbrc.jp/research/db/TFSEARCH.html).normal controls among the male children
χ2 P OR [95%CI]
rolsb
1.717 0.190 1.556 [0.802–3.018]
0.812 0.368 1.426 [0.658–3.091]
lymorphisms, from left to right. No T-T haplotype was observed.
Table 7 Genotype and allele frequencies of the TPH2 SNP rs4565946 in normal population of different races
Polymorphism Number and frequency (%)
Chinese (the paper) CHB (H) ASW (A) CEU (C) GIH (G) JPT (J) MEX (M) TSI (T)
TPH2 rs4565946
N 125 137 57 113 101 113 58 101
CC 65(52.0) 81 (46.6) 44 (77.2) 30 (26.5) 40 (39.6) 49 (43.4) 29 (50.0) 34 (33.7)
CT 53 (42.4) 63 (46.0) 10 (17.5) 51 (45.1) 47 (46.5) 51 (45.1) 27 (46.6) 43 (42.6)
TT 7 (5.6) 8 (5.8) 3 (5.3) 32 (28.3) 14 (13.9) 13 (11.5) 2 (3.4) 24 (23.8)
Pa 0.975 0.004 <0.001 0.046 0.175 0.756 <0.001
C 183 (73.2) 195 (71.2) 98 (86.0) 111 (49.1) 127 (62.9) 149 (65.9) 85 (73.3) 111(55.0)
T 67 (26.8) 79 (28.8) 16 (14.0) 115 (50.9) 75 (37.1) 77 (34.1) 31 (26.7) 91 (45.0)
Pb 0.604 0.007 <0.001 0.019 0.085 0.988 <0.001
TPH2 rs4570625
N 125 136 57 113 101 113 57 102
GG 24 (19.2) 30 (22.1) 26 (45.6) 73 (64.6) 63 (62.4) 28 (24.8) 25 (43.9) 60 (58.8)
GT 57 (45.6) 71 (52.2) 25 (43.9) 33 (29.2) 32 (31.7) 58 (51.3) 27 (47.4) 33 (32.4)
TT 44 (35.2) 35 (25.7) 6 (10.5) 7 (6.2) 6 (5.9) 27 (23.9) 5 (8.8) 9 (8.8)
Pa 0.251 <0.001 <0.001 <0.001 0.150 <0.001 <0.001
G 105 (42.0) 131 (48.2) 77 (67.5) 179 (79.2) 158 (78.2) 114 (50.4) 77 (67.5) 153 (75.0)
T 145 (58.0) 141 (51.8) 37 (32.5) 47 (20.8) 44 (21.8) 112 (49.6) 37 (32.5) 51 (25.0)
Pb 0.158 <0.001 <0.001 <0.001 0.065 <0.001 <0.001
Abbreviations: TPH2, tryptophan hydroxylase2.
CHB (H), Han Chinese in Beijing, China; ASW (A), African ancestry in Southwest USA; CEU (C), Utah residents with Northern and Western European ancestry from
the CEPH collection; GIH (G), Gujarati Indians in Houston, Texas; JPT (J), Japanese in Tokyo, Japan; MEX (M), Mexican ancestry in Los Angeles, California; TSI (T),
Tuscan in Italy;
a Pearson Chi square test was used to calculate the p-values.
b Chi square test was used to calculate the p-values. Continuity Correction was used when the minimum expected was <5.
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quencies of the rs4570625 G allele than the normal con-
trols in males, suggesting that the G allele might increase
the risk of TD in the Chinese Han population.
Additional evidence has shown that the T allele of
rs4570625 is related to the low expression of TPH2
and increased activity in the prefrontal brain [31,32].Figure 1 Structure of the predicted transcription factor binding sites.
allele. B: Transcription factor binding sites for function prediction in minorJames F et al. demonstrated that levels of tryptophan
in cerebrospinal fluid were inversely associated with tic
severity in TS subjects [33]. In our studies, we found
an increase in G-allele in high score subgroup of male
TD children. For rs4570625, the allele G type might
affect the transcription factor binding ability (CdxA
and HSF); therefore, the allele G type can change theA: Transcription factor binding sites for function prediction in major
allele.
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http://www.behavioralandbrainfunctions.com/content/9/1/6transcription regulation of the TPH2 gene. The results
indicated that the allele G of rs4570625 might have re-
lationship with the severity of tic symptoms among
male TS children in the Chinese Han population.
A recent study provided evidence that promoter
rs4570625 polymorphism was not associated with down-
regulated expression of TPH2 [30]. Whether SNP
rs4570625 is a direct disease-causing polymorphism,
therefore, remains a subject of further study.
To the best of our knowledge, no previous studies
have investigated whether the intronic variant (SNP
rs4565946) has any functional effects. In our study, the
intronic polymorphism rs4565946 resulted in strong
linkage disequilibrium (D’ = 0.933, r2 = 0.429) with a
functional polymorphism of rs4570625. Considering the
association of TD with the T-G and C-G haplotypes, and
given results for each SNP and the observation that the
C allele located in intron 2 is in linkage disequilibrium
with the functional T allele of the promoter SNP, it is
possible that the intronic variant may also be function-
ally important in the development of TD.
There are a number of limitations to the present study.
Firstly, the relatively small sample size and only two SNPs
were studied, may have reduced the power to detect the
main effects of (serotonin-related) TPH2 gene polymorph-
isms and limit the generalization of our results to the
population as a whole. Secondly, nearly 23.5% of TD chil-
dren in our study had ADHD, therefore, our results could
be confounded by co-existing ADHD. Thirdly, no infor-
mation was available about the medications and behavioral
therapeutic interventions of the TD patients at the recruit-
ment. For these reasons our data should be interpreted
cautiously.Conclusions
This is the first study to assess whether polymorphic
variants of TPH2 are associated with TD in the Chinese
Han population. Our results clearly link TPH2 variations
to the pathogenesis of TD and further support the etio-
logical relevance of 5-HT signaling in TD.Additional file
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